Familial Mediterranean fever, from pathogenesis to treatment: a contemporary review

ABDURRAHMAN TUFAN
HELEN LACHMANN

Follow this and additional works at: https://journals.tubitak.gov.tr/medical

Part of the Medical Sciences Commons

Recommended Citation
TUFAN, ABDURRAHMAN and LACHMANN, HELEN (2020) "Familial Mediterranean fever, from pathogenesis to treatment: a contemporary review," Turkish Journal of Medical Sciences: Vol. 50: No. 10, Article 3. https://doi.org/10.3906/sag-2008-11
Available at: https://journals.tubitak.gov.tr/medical/vol50/iss10/3

This Article is brought to you for free and open access by TÜBİTAK Academic Journals. It has been accepted for inclusion in Turkish Journal of Medical Sciences by an authorized editor of TÜBİTAK Academic Journals. For more information, please contact academic.publications@tubitak.gov.tr.
Abstract: Familial Mediterranean fever (FMF) (OMIM #249100) is the most common hereditary autoinflammatory disease in the world. FMF is caused by gain of function mutations of MEFV gene which encodes an immune regulatory protein, pyrin. Over the last few years, we have witnessed several new developments in the pathogenesis, genetic testing, diagnosis, comorbidities, disease related damage and treatment approaches to FMF. Elucidation of some of the pathogenic mechanisms has led to the discovery of pathways involved in inflammatory, metabolic, cardiovascular and degenerative diseases. The use of next generation sequencing in FMF has revealed many new gene variants whose clinical significance may be clarified by developing functional assays and biomarkers. Clinically, although FMF is considered an episodic disease characterized by brief attacks, recent systematic studies have defined several associated chronic inflammatory conditions. Colchicine is the mainstay of FMF treatment, and interleukin (IL)-1 antagonists are the treatment of choice in refractory or intolerant cases. Experience of IL-1 antagonists, anakinra and canakinumab, is now available in thousands of colchicine resistant or intolerant FMF patients. In this contemporary review, we surveyed current FMF knowledge in the light of these recent advances.

Key words: Familial Mediterranean fever, genetics, pathogenesis, diagnosis, clinical features, treatment, prognosis

1. Introduction
Familial Mediterranean fever (FMF) is the most common hereditary autoinflammatory disease in the world. It primarily affects populations originated from East Mediterranean territory though patients are reported worldwide. FMF is caused by gain of function mutations in the MEFV gene, which encodes a protein called pyrin which has regulatory functions on the innate immune system. For many years the high carrier frequency for MEFV mutations in Middle Eastern populations was thought to confer a selective advantage for an unknown human threat and recent data suggests that it includes the cause of the “black death”, Yersinia pestis [1].

FMF is characterized mainly by recurrent short-lived episodes of peritonitis, pleuritis, arthritis, rash, and usually with accompanying fever. Recent systematic studies have defined a variety associated inflammatory conditions in the setting of FMF. As genetic testing has become cheaper and widely available it is increasingly used in daily clinical practice. Next generation sequencing (NGS) has identified many new variants but their clinical associations are largely unknown, hampering their interpretation. Functional assays and biomarkers that may aid in diagnosis, assessment of disease severity and treatment are under development [2]. Practical indices quantifying FMF disease severity, activity and recently damage accrual have been developed and validated for clinical use and research purposes [3–5].

Colchicine is the mainstay of FMF treatment, and interleukin (IL)-1 antagonists are the treatment of choice in refractory or intolerant cases. The use of IL-1 antagonists, anakinra and canakinumab, has now reached thousands of colchicine resistant or intolerant FMF patients. In this contemporary review, we surveyed current FMF knowledge in the light of these recent advances.

This work is licensed under a Creative Commons Attribution 4.0 International License.
new developments in FMF pathogenesis, genetic testing, comorbidities and their management, disease related damage and treatment approaches. In this contemporary review, we presented the current knowledge on FMF in the light of recent advances.

2. Literature search strategy
We conducted a literature search on FMF from 1967 to May 2020 using the Medline, Embase, and Cochrane databases and the following terms: ‘pathogenesis’, ‘genetics’, ‘manifestation’, ‘chronic inflammation’, ‘treatment’, ‘complication’, ‘amyloidosis’, ‘prognosis’, and ‘familial Mediterranean fever’. We reviewed abstract archives of the International Society of Systemic Auto-Inflammatory Diseases (ISSAID), European League Against Rheumatism (EULAR), and American College of Rheumatology (ACR) congresses for unpublished data on specific topics of interests such as colchicine resistance and intolerance. All the articles we surveyed were included in Endnote library, and duplicate articles were removed from the library. We limited our search to articles published in the English language.

3. Genetics and pathogenesis
Unusually for a disease largely inherited in an autosomal recessive fashion, FMF results from gain of function mutations of Mediterranean fever gene (MEFV), located on chromosome 16 (16p13.3) [7]. MEFV encodes for a 781 amino acid protein, pyrin (‘pyrin’ or ‘marenostrin’, TRIM20) which exist in several isoforms both in cytoplasm and nucleus [8]. The exact function of pyrin in nucleus is largely unknown. Pyrin has at least four functional domains; PYD, bBOX, CC and B30.2/SPRY. Upon activation, pyrin oligomerizes with other cellular proteins, forming a macromolecular complex called ‘pyrin inflammasome’ that activates caspase-1 which in turn, mediates the release of pro-inflammatory IL-1β and IL-18 from their inactive precursors and pyroptosis via the gsdmerin D pathway [1, 9].

Cytoplasmic pyrin interacts with microtubules in cell skeleton and is a member of cytosolic pattern recognition receptors (PRRs) which are responsible for the initiation of rapid innate immune responses by sensing endogenous danger- or exogenous pathogen-associated molecular patterns (DAMPs and PAMPs). However, unlike other receptors, pyrin does not recognize DAMPs/PAMPs directly, but rather detects alterations in cytoplasmic homeostasis, incited by harmful stimuli, termed “homeostasis-altering molecular processes” (HAMPs). These modify RhoA GTPase within cells [10]. In physiologic conditions, RhoA GTPase activates the serine-threonine kinases; PKN1 and PKN2, that bind and phosphorylate pyrin. Phosphorylated pyrin binds to inhibitory 14-3-3 proteins and this process retains pyrin in an inactive state that prevents formation of the pyrin inflammasome. In FMF, mutations in MEFV gene impair interaction of pyrin with microtubules, PKN and 14-3-3 proteins facilitating formation of a proinflammatory pyrin inflammasome. When the pyrin inflammasome assembled, it activates caspase-1 to process pro-IL-1β and pro-IL-18 to their mature forms IL-1β and IL-18, respectively, and cells undergo an inflammatory death termed pyroptosis. Over activation of the pyrin inflammasome, and the resulting inflammation drives typical febrile inflammatory attacks observed in FMF [10,11].

IL-1β stimulates expression of genes involved in the entire IL-1 pathway, thereby enhancing its own production, contributing to an inflammatory burst [12]. Expression of pyrin can be upregulated by various cytokines: interferon (IFN)-γ, Tumor Necrosis Factor (TNF)-α, IL-4, and IL-10 as well as Lipopolysaccharides (LPS) [10]. Pyrin is mainly expressed in innate cells – including granulocytes, cytokine-activated monocytes, dendritic cells, and synovial as well as serosal fibroblasts – which explains the typical organ sites involved in FMF. Although episodic nature of FMF is not completely understood, during attacks neutrophil extracellular traps (NETs), i.e. chromatins filaments ‘decorated’ with neutrophilic proteins and captured IL-1β, are formed, restricting further generation of IL-1β by a negative feedback mechanism, which may explain the self-limited nature of FMF attacks [13].

MEFV gene has 10 exons and there are more than 370 variants identified to date. The number of variants are increasing with use of genome sequencing. Most of the pathogenic/likely pathogenic variants are located on exon 10 which encodes B30.2/SPRY domain, responsible for the activation of caspase-1. The most common MEFV variant is M694V (c.2080A>G) in FMF endemic areas. Other frequent exon 10 variants are M694I (c.2082G>A), V726A (c.2177T>C) and M680I (c.2040G>C and c.2040G>A) and these variants constitute almost 75% of all FMF patients (Table 1) [14,15]. Carriage of these variants is associated with the typical clinical phenotype of FMF and with more severe disease [16]. Benign and likely benign variants are usually located on exon 2 and generally do not cause typical phenotype of FMF. Up to two thirds of registered variants distributed over the entire gene are either not classified or classified as variant of uncertain significance (VUS) due to their unknown clinical association [17].

FMF is inherited as autosomal recessive pattern, however approximately 30% of patients harbour single pathogenic variant (monoallelic disease) [18]. In FMF

---

1. The Human Protein Atlas (2020). MEFV [online]. Website https://www.proteinatlas.org/ENSG00000103313-MEFV/tissue [accessed 00 Month Year].

2. Infevers (2020). MEFV sequence variants [online]. Website https://infevers.umai-montpellier.fr/web/search.php?q=1 [accessed 00 Month Year].
prevalent countries and high rate of consanguineous marriages accumulation of individuals from consecutive generations might be perceived as dominant inheritance which is indeed pseudo-dominant transmission. However, some of MEFV variants with true dominant inheritance have also been defined [19,20]. Symptom-free individuals with one identifiable pathogenic MEFV gene variant are called ‘asymptomatic carriers’ of the disease, and symptom-free individuals harbouring two pathogenic variants are defined as ‘phenotype 3’ [21].

4. Epidemiology
FMF is prevalent in populations originating from the Eastern Mediterranean region – namely, Turks, Jews, Arabs, and Armenians. However hundreds of patients are reported from Europe, North America and Japan [22,23], and this figure is expected to increase due to massive population movements from endemic areas to these latter regions over the last two decades. FMF’s prevalence varies from 1:500 to 1:1,000 in endemic countries [22] with the highest reported prevalence of 1/395, from central Anatolia region [24]. Considering disease prevalence and population size, Turkey has the highest number of FMF patients in the world followed by Israel and Armenia [22].

5. Clinical picture
FMF is characterized by recurrent short-lived inflammatory attacks which resolve spontaneously within 1–3 days. The well-known, canonical manifestations of FMF are fever, serositis, arthritis and erysipelas like erythema [25]. Additionally, a wide array of clinical presentations – such as neurologic, thrombotic, and ocular disease – have been reported in FMF settings and referred to as ‘noncanonical manifestations’ [26]. Some FMF patients may develop complications of disease in their follow up and some others may initially present with them, typical example of the latter is the presentation with amyloid A (AA) amyloidosis in the absence of classical symptoms which is termed as phenotype 2.

FMF attacks usually start from early childhood and 80%–90% of patients become symptomatic before the age of 20 years [25]. Initial manifestations of the disease after age 40 are fairly rare, and often characterized by a mild disease course [27]. FMF patients generally recognize provoking trigger – such as emotional stress, cold exposure, menstruation, or travel – before the onset of symptoms [28,29]. Early or premonitory symptoms such as loss of appetite, irritability and extremity numbness are described by almost 50% of patients hours before the onset of full blown attacks [30]. These prodromal symptoms are more common in men and before the onset of peritonitis and arthritis attacks [31]. Many individuals describe a typical individual recurrent attack pattern, which may help to differentiate attacks from other conditions, such as acute appendicitis or cholecystitis.

Frequency of type of FMF manifestations differ between studies according to the enrolled age group, geographic region and ethnic population. However, fever and peritonitis are by far the most common manifestations, reported in more than 90% of patients in all age and ethnic groups [16,22]. FMF associated fever usually starts suddenly, spikes within hours and resolves spontaneously on the same day. The pattern of fever may help to differentiate FMF from infectious causes and other autoinflammatory diseases [32]. Fever may occur alone or accompany other FMF manifestations. In rare instances, fever might be the only or initial symptom which could be handled as fever of unknown origin [33,34].

Peritoneal attacks start localized and spread rapidly involving the entire abdomen. Peritoneal inflammation causes a typical ileus picture and patients suffer from crippling stomach pain. Physical examination reveals

| Benign   | Likely benign | VUS    | Likely pathogenic | Pathogenic |
|----------|--------------|--------|-------------------|------------|
| D102D    | R75Q         | E148Q  | S208T             | M680I>C    |
| G138G    | P115T        | P369S  | F479L             | M680I>G>A  |
| R202Q    | G304R        | H478Y  | M680L             | M694V      |
| R314R    | A317T        | G678E  | I692DEL           | M694I      |
| E474E    | A457V        | T681I  | M694L             | V726A      |
| D510D    | I591M        | I720M  | K695R             |            |
| P588P    | V690L        | V722M  | K695N             |            |
| S675N    | I772V        | A744S  | R761H             |            |

1 Infevers (2020). MEFV sequence variants [online]. Website https://infevers.umai-montpellier.fr/web/search.php?n=1 [accessed 30 May 2020].
rigidity of the abdominal muscles, rebound tenderness, and loss of bowel sounds – an emergency scenario clinically indistinguishable from the surgical causes of acute abdomen. Thus, a history of unrevealing abdominal surgery is common among FMF patients (Figure 1A). In suspected cases, imaging studies may help to exclude surgical pathologies. A mild rebound diarrhea may follow abdominal attacks. Despite their dramatic presentation, all signs and symptoms of peritonitis completely resolve without a sequel over 24–72 h, though chronic ascites and peritoneal adhesions have been reported rarely [35].

Less than 50% of patients experience pleural attacks, which manifest as sudden-onset, unilateral pleuritis and may occur either alone or in combination with peritonitis and fever. Patients describe typical severe pleuritic chest pain and, upon examination, their breath sounds are diminished on the affected side of their chest. Chest X-rays may reveal a small exudate at the costophrenic angle. Attacks usually resolve completely within one to three days [36,37].

Pericarditis is a rare condition observed in 1%–2% of patients [38]. Pericarditis gives symptoms as retrosternal chest pain and dyspnea. Cardiac tamponade may occur very infrequently. An electrocardiogram shows an elevated ST segment, chest X-rays may reveal transient enlargement of the cardiac silhouette (Figures 1B and 1C), and echocardiography shows accumulation of pericardial fluid [39]. Rarely, recurrent pericarditis can be the sole manifestation of FMF, which might be confused with idiopathic pericarditis [40,41].

Arthritis is the third most common manifestation of FMF affecting more than 50% of patients. Articular attacks occur as sudden-onset, painful, swollen joints. These attacks involve one or two large joints of the lower extremities and can be accompanied by fever, a condition indistinguishable from septic arthritis (Figures 2A and 2B). Joint aspirate reveals a sterile inflammatory effusion (Figure 2C). Symptoms peak in one to three days and subside spontaneously within a week. Protracted arthritis is observed in fewer than 5% of patients, and permanent damage may occur in a small proportion of patients – particularly when the hip joints are involved (Figure 3). Chronic sacroiliitis is reported in approximately 10% of FMF patients [42]. Articular attacks are more common in patients harbouring an M694V mutation, and it is associated with more severe disease as well as increased risk of AA amyloidosis [43].

Muscular complaints are common in FMF patients, particularly those carrying the M694V mutation. The most common muscular symptom is standing myalgia (exertional leg pain) which occurs in calf muscles. Attacks might be evoked by long travel and probably by passive vibration. Myalgia is associated with more severe disease and persistent inflammation [44,45] that can be easily overlooked if not meticulously questioned. The most severe muscular presentation is protracted febrile myalgia (PFM) which is characterized by intense myalgia and fever with prolonged complaints up to 10 weeks. PFM causes a marked acute-phase response, and magnetic resonance imaging reveals muscle oedema (Figure 4). The condition is refractory to colchicine and may even occur despite regular colchicine use [46].

The skin manifestations of FMF present as a patchy skin rash resembling typical erysipelas (erysipelas-like erythema, ELE) or as painful purpura resulting from leukocytoclastic vasculitis (Figure 5). Skin attacks usually follow long travel or prolonged walking and occur mostly on the legs, around the ankle, or on the dorsum of the feet.

A wide array of presentations – including vasculitic, neurologic, thrombotic, ocular, and cochlear disorders– have been reported in FMF patients and defined as ‘non-canonical manifestations’ [26]. However, the prevalence and pathogenetic associations of them with FMF have not been well characterized in most of these disorders, which might also be interpreted as coincidental occurrences [47].

It has long been noted that FMF patients and asymptomatic carriers are vulnerable to certain inflammatory diseases, such as spondyloarthritis, Henoch–Schönlein purpura (HSP), and polyarteritis nodosa (PAN) [48]. The increased incidence of these particular diseases in FMF patients can be explained by an enhanced expression of proinflammatory cytokines and microRNAs. Recent publications have expanded this list to include: juvenile idiopathic arthritis, PFAPA, spondyloarthropathies, inflammatory bowel disease, vasculitides (Behçet’s disease, HSP, PAN), glomerulonephritis, skin diseases (psoriasis, hidradenitis suppurativa, contact dermatitis), and demyelinating brain disease [48–52]. Most of these comorbid conditions fall under MHC Class I group diseases (MHC-I-opathies), whereas MHC–II–spectrum (autoimmune) diseases have a comparable prevalence among the general population [48,49].

Phenotype 2 FMF is characterized by initial presentation with AA amyloidosis in the absence of other classical manifestations of FMF disease. This phenotype constitutes fewer than 2% of patients in different cohorts [38]. Diagnosis requires genetic analysis and exclusion of other causes of chronic inflammation.

Although FMF is characterized by intermittent inflammatory attacks, a substantial number of patients have chronic, ongoing inflammation. In a prospective study, only 29% of serum amyloid A (SAA) measurements in FMF patients were less than 3 mg/L, 65% were less than 10 mg/L, and 13% exceeded 50 mg/L [53]. Independent risk factors for chronic inflammation were male sex, M694V
homozygosity, musculoskeletal-type attacks, colchicine resistance, and inflammatory comorbidities [54]. Chronic inflammation constitutes a major risk for the development of amyloidosis, kidney failure and other complications of disease [54,55].

6. Genetics and environmental factors’ effects on phenotypic variation

The heterogeneous disease course of FMF results from a complex interplay between genetic and environmental factors. The final disease phenotype primarily determined by the MEFV variants carried [14]. M694V is the most common and the most penetrant variant causing more pronounced caspase-1, IL-1 family cytokine and S100A12 secretion from neutrophils [56].

Patients harbouring biallelic exon 10 variants – particularly variants which are homozygous for M694V – exhibit a severe disease phenotype characterized by an earlier age of onset, more frequent attacks, musculoskeletal features, lower colchicine response, chronic inflammation, increased risk of comorbid conditions, and disease complications including infertility, joint damage, and
secondary amyloidosis [38, 57–59]. Disease associated with a single mutation (MEFV heterozygotes) typically is milder than in individuals with homozygous or compound heterozygous pathogenic variants, characterized by later onset, less frequent fever/serositis type attacks, more favorable response to colchicine and lower risk of disease complications [60,61]. However this is not always the case and reports exist of more severe single variant disease which might be due to inclusion of high number of patients carrying single heterozygous M694V mutation [62]. Approximately 10%–20% of FMF patients in different cohorts do not carry any identified MEFV mutation though it is contentious whether this condition is FMF-like disease or true FMF with as yet unidentified genetic variations [14]. Nevertheless, after extensive genetic testing there are a number of confirmed mutation negative patients who show a mild disease phenotype similar to those with single heterozygous subjects [63].

The symptoms and severity of FMF can vary among affected individuals with the same MEFV variant, even among members of the same family [64] suggesting contributions by a number of modifiers – including other genes, epigenetic and environmental factors. Based on twin studies relative contribution of MEFV, non-MEFV genetic factors and environmental factors on phenotypic variation are estimated at a ratio of 6:1.5:1, respectively [65]. The known MEFV
independent genetic modifiers are polymorphisms of IL-1β which is associated with disease severity [66] and harboring alpha/alpha genotype for serum amyloid A protein 1 (SAA1) gene which increases the risk of developing AA amyloidosis without affecting FMF disease characteristics [67]. Although specific alterations have been reported in epigenetics such as microRNAs and DNA methylation, their contribution to phenotypic variation has yet to be clarified [68–70]. The influence of specific environmental factors on FMF phenotype have not been defined, but country of residence is repeatedly reported as an independent modifier with living in Turkey, Armenia and Middle East increasing risk of severe disease and AA amyloidosis [71–74].

7. Diagnosis
The diagnosis of FMF is made based on the patient history, inflammatory markers and more recently by genetic testing. Several clinical diagnostic criteria sets have been proposed for the diagnosis of FMF. The Tel Hashomer criteria, Livneh criteria and Turkish pediatric criteria all rely on the clinical symptoms, family history and colchicine response. The oldest and maybe the most widely used criteria set is the Tel Hashomer, which includes fever, peritonitis, pleuritis, arthritis, ELE, amyloidosis and family history [25]. In 1997, Livneh et al. created a new set derived from the Tel Hashomer criteria but including exertional leg pain and laboratory findings (inflammatory markers and urinary findings, proteinuria/hematuria) and excluding amyloidosis. Both extended and simplified versions of Livneh criteria have a reported sensitivity and specificity of >95% [75]. In 2009, Turkish paediatric criteria for FMF were developed with the inclusion of family history and clinical characteristics of fever, arthritis, stomach, and chest pain. Children with two or more of these criteria can be diagnosed with FMF with a reported sensitivity and specificity of 86.5% and 93.6%, respectively [76].

Clinical criteria are supposed to be sufficient for the diagnosis of FMF in endemic countries [22]. However, diagnosis of FMF can be difficult and delayed with use of clinical criteria, if the physician experience of FMF symptoms is limited and when the patient has hazy or atypical symptoms. After molecular cloning of MEFV, genetic testing become available as a diagnostic adjunct, especially in atypical cases and phenotype 2 patients. Recently, Eurofever/PRINTO group released classification (not diagnostic) criteria combining genetic test results and the following clinical features; attacks lasting 1–3 days, arthritis, abdominal and chest pain [77]. According to Eurofever/PRINTO, individuals with biallelic pathogenic/likely pathogenic variants and one clinical feature are classified as FMF, whereas patients harbouring one pathogenic or likely pathogenic variant or low penetrant biallelic variants are required to have two or more clinical features in order to be classified as having FMF. The performance of three clinical FMF diagnostic criteria and the new Eurofever/PRINTO classification criteria was recently tested in a real-life setting on paediatric patients. All of the criteria sets revealed similar performance in diagnosing or classifying patients with biallelic pathogenic variants, but the Eurofever/PRINTO classification criteria had a somewhat lower sensitivity for patients with monoallelic variants (heterozygotes) [78,79].

Genetic testing is recommended in suspicion of FMF in non-endemic countries to support/confirm diagnosis but also give valuable information about the severity of disease, like colchicine response, risk of disease complications and ultimately long-term prognosis [80,81]. Genetic testing can be performed either by Sanger or single gene NGS. ISSAID/European Molecular Genetics Quality Network (EMQN) recommends a limited initial MEFV exon 10 sequencing in patients with suspected of FMF [82]. NGS might reveal many clinically undetermined variants.
complicating interpretation of test results. A recently reported consensus-driven pathogenicity classification failed to classify almost half of the MEFV variants (42.4%) [83]. Functional assays may ascertain pathogenicity of such variants but these have not been performed for many of them [81]. Lamkanfi et al. recently developed a functional diagnostic test for FMF, ex vivo colchicine assay, with a sensitivity of 86% and specificity of 100%. The test was based on colchicine's in vitro inhibitory effect on peripheral blood mononuclear cells for the secretion of IL-1β and IL-18 via stimulation with Clostridium difficile toxin A [2].

Commonly used markers of inflammation leukocyte count, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), serum amyloid A protein (SAA) and fibrinogen are increased during attacks and should return to their normal values in between attacks. CRP, SAA and fibrinogen are produced from liver upon stimulation with proinflammatory cytokines including IL-1β, IL-6, TNF-α and IFN-γ. SAA is found in trace amounts in plasma (normal range <3 mg/L) and its concentration can rapidly increase up to 1000-fold within 24 h in response to inflammatory stimuli [84]. SAA is the precursor of AA amyloid fibrils and sustained long-term elevation of SAA concentration is the only known prerequisite for the development of AA amyloidosis [53]. Similarly, CRP values can rise dramatically up to hundred-folds after an inflammatory stimulus. In a prospective study, Lachmann et al. showed that both SAA and hs-CRP were massively elevated during all reported clinical attacks of FMF in all patients, with median values of 693 (range of 140–1330) mg/L and 115 (range of 26–296) mg/L, respectively [53]. Hence, SAA is the most sensitive biomarker and is recommended to adjust colchicine dose and minimize the risk of AA amyloidosis. Although acute phase proteins (APRs) are helpful in corroborating clinical attacks and inflammatory activity, they all lack specificity for diagnostic use.

8. Differential diagnosis of FMF
Several diseases may mimic the symptoms of FMF, and they should be considered during diagnosis and in the case of colchicine nonresponse (Table 2).

9. Treatment
The goals of treatment in FMF are improving quality of life (QoL), reducing frequency, severity and duration of attacks and prevention of long term damage, particularly AA amyloidosis by minimizing chronic/subclinical inflammation. There is great heterogeneity between individuals for the type and severity of attacks. Hence, treatment should be tailored individually with monitoring attacks and inflammatory markers/proteinuria [87]. FMF treatment can be divided into three parts:

- Attack and AA amyloidosis prophylaxis,
- Treatment of acute episodes,
- Management of comorbid conditions and complications.

Prior to 1972 and the seminal observation that colchicine prophylaxis decreases FMF attacks and subsequently the risk of AA amyloidosis, more than 50% of patients died prematurely from complications. Therefore, under this approach, patients should be monitored for the onset of new symptoms that direct alternative diagnoses while maintaining colchicine.

| Table 2. Differential diagnoses of familial Mediterranean fever. |  |
|---|---|
| Mevalonate kinase deficiency (MKD) | Inflammatory bowel disease |
| TNF receptor-associated periodic syndrome (TRAPS) | Porphyria |
| Periodic fever, aphthous stomatitis, pharyngitis, and adenopathy (PFAPA) | Median arcuate ligament syndrome |
| Hereditary angioedema | Intestinal adhesion |
| Fabry disease | Adrenal failure |
| Cyclic neutropenia | Chronic recurrent infections |
| Yao syndrome | Mesothelioma |
of patients with FMF died of amyloidosis [25,88]. But even recently AA amyloidosis is a major problem among FMF patients affecting up to 10% of patients in large series [89]. Four randomized controlled trials (RCTs) [90–93] and decades of experience concretize colchicine's safety and efficacy in FMF treatment. The risk of amyloidosis in patients who adhere to colchicine therapy is less than 1% in the long term – even in the absence of a complete control of attacks [88]. Therefore, lifetime colchicine prophylaxis is recommended in all FMF patients, regardless of symptoms, unless a severe side effect ensues.

Colchicine is an ancient agent used for centuries for the treatment of gout. Although its precise mechanism of action is unknown, colchicine has inhibitory functions on microtubule polymerization, adhesion molecules, neutrophil chemotaxis, and NLRP3 inflammasome [94]. It is thought to exert these effects primarily on neutrophils due to selected accumulation in these cells as they lack the P glycoprotein efflux pump [95]. Colchicine's bioavailability ranges from 24% to 88% while its elimination half-life ranges from 20 to 40 h and is prolonged in patients with liver and kidney impairment [94]. It has a narrow therapeutic index while being clinically effective in most FMF patients at blood concentrations <7 ng/mL, but it can cause serious toxicities, multiple organ failure, and death at concentrations >10 ng/mL [96]. Oral doses of 1–1.5 mg/day is the optimal dose in most patients for the prevention of attacks and AA amyloidosis [22,97]. But the dosage can be increased to a maximum of 2.5–3 mg/day if the response is inadequate [97–99]. In previous long-term studies with large number of pediatric and adult patients, titrating the dose to control symptoms resulted in less than 1% risk of proteinuria [98]. However, it’s prudent to keep dosage ≥1.5 mg/day in patients with or at high risk of AA amyloidosis, provided that the liver and kidney functions are normal [100]. The dose can be taken once or divided according to gastrointestinal tolerance. Colchicine is safe and even improves pregnancy outcome, so it must be continued during pregnancy and while breastfeeding [96, 98].

The foremost side effects of colchicine are diarrhoea, elevation in transaminases, leukopenia, and neuromuscular toxicity – which all require regular monitoring. Colchicine strongly interacts with tubulin, cytochrome P3A4 (CYP3A4), and P-glycoprotein. Therefore, the risk of toxicity increases when colchicine is combined with drugs or foods which are substrates of these proteins. Many fatalities have been reported with the combined use of clarithromycin, cyclosporin, lipid-lowering drugs, and grapefruit [94]. Howbeit, colchicine is generally safe, requiring permanent cessation in 2% of patients in long term [101]. Nonetheless, colchicine intolerance constitutes a major problem, with almost one-fifth of patients unable to maintain optimal doses [101]. In a large cohort, diarrhoea (10.8%), transaminitis (5.9%), leukopenia (1.1%), renal impairment (1.3%), myopathy (0.5%), and occasional skin side effects hindered optimal colchicine dosing [101]. Of note colchicine frequently unmasks lactose intolerance and GI side effects can often be ameliorated by introduction of a lactose free diet, particularly in those with a high milk or other dairy product intake.

Ultimately, colchicine at doses of 1–2 mg/day, titrated according to response, has provided 64% complete and 31% partial response in the long term [102]. However, about 5%–10% of patients do not respond well to colchicine, requiring additional treatment [102]. Patients with M694V homozygous or biallelic exon 10 variants, severe disease, or musculoskeletal and skin manifestations are more likely to be colchicine-nonresponsive, whereas patients with serositis or fever-type attacks and single-heterozygous variants may respond to lower colchicine doses [103]. Colchicine cessation can be possible in the latter group provided that they are in complete remission for at least for 3–5 years, has normal acute phase levels, at low risk of AA amyloidosis and adhere with regular follow up [104,105]. However, most physicians prefer lifelong colchicine prophylaxis. Nevertheless, colchicine-free long-term remission is possible in minority of patients [104].

9.1. Treatment of colchicine-resistant or -intolerant patients
No clear consensus offers a precise definition of ‘colchicine resistance’, but experiencing monthly attacks or persistently elevated inflammation markers despite the adherence of a maximally tolerated colchicine is the most widely accepted definition [99,106]. Colchicine-resistant (crFMF) or colchicine-intolerant (ciFMF) patients are candidates for biologic therapies, but guidelines for their use are lacking. Therefore, before starting biologics, there are several issues to consider: patients’ quality of life, work productivity and disposition, the presence of chronic inflammation, and reimbursement for drug costs. Furthermore, causes of nonresponse should be carefully reviewed, including attack mimics, comorbid conditions, potent attack inducers, malabsorption and, most importantly, treatment adherence [96,107]. Avoidance of precipitating factors – such as cold exposure, strenuous exercise, certain drugs, and certain foods – might reduce the frequency of attacks. A prospective observation period of three to six months to confirm attacks and determine inciting factors is recommended before the use of biologic drugs [108].

Three IL-1 antagonists have been studied in the treatment of crFMF: anakinra, canakinumab, and rilonect. All of the IL-1 antagonists significantly reduce the number of attacks and improve quality of life with good safety profiles [108,109]. Good quality studies are scarce for the use of IL-1 antagonists and all randomized
or open label studies included relatively small numbers of patients. Most of the evidence comes from single case reports or case series. The most commonly used drugs for crFMF are anakinra and canakinumab [110]. There are no comparative studies between agents for canakinumab vs. anakinra, so both agents can be used for the management of crFMF and ciFMF patients. Their long-term efficacy and safety are unknown, but they are effective in stabilizing and improving FMF complications such as proteinuria in the short term, suggesting potential benefits in the long term [111,112]. Hence, until the long-term effects of IL-1 antagonists are demonstrated, colchicine should be coadministered unless it is contra-indicated. The rate of infection is low with use of IL-1 antagonists and the main limitation for their use is their financial expense.

Anakinra, a recombinant IL-1 receptor antagonist (rHIL-1Ra), was the first IL-1 blocking biologic agent produced and inhibits binding of both IL-1α and IL-1β to the IL-1 receptor. It is the most extensively used IL-1 blocker in FMF treatment and, currently, the cheapest one [108]. Anakinra was studied in only one RCT included 25 FMF patients (12 in anakinra and 13 in placebo arms). All 12 patients responded, and seven (58.3%) were complete responders [113]. Anakinra has a relatively short half-life (4–6 h) requiring daily injections. An advantage of the short half-life is that it can be used as a diagnostic challenge test for the suspected IL-1 mediated diseases [114] and also to determine whether an unusual manifestation relates to FMF itself [115]. Moreover, anakinra’s short half-life allows its use in the preattack prodromal period to alleviate the symptoms of an impending attack. The prophylactic, intermittent, short-period use of anakinra before exposure to known predictable triggers, such as menstruation and travel, might also be effective [116]. The recommended dose for anakinra is 1–2 mg/kg/day with a maximum daily dose of 8 mg/kg. The usual treatment dose is 100 mg/day, and the dose can be escalated according to patient response – though multiple doses are hardly tolerated by patients due to painful injections. The mean plasma clearance of anakinra decreases by 70%–75% in patients with end-stage renal disease (ESRD), requiring a dosage adjustment (i.e. starting with a dose of 100 mg every other day). Other significant side effects are skin reactions, leukopenia, infections, and weight gain (Figure 6). Loss of efficacy may occur in long-term use, which is an indication for switching to canakinumab treatment [110].

Canakinumab differs from anakinra in that it specifically blocks IL-1β. It has a mean plasma half-life of 26 days, allowing for monthly or bimonthly administrations. Canakinumab is the only licensed drug in Europe and the United States for the treatment of crFMF. Two open-label trials and one RCT evaluated canakinumab’s efficacy. Once-every-four-weeks doses of 150 mg (2 mg/kg in children) of canakinumab provided a complete response of 61% in CLUSTER trial, and when the dose doubled for patients with partial responses (300 mg in adults, 4 mg/kg in children, every four weeks), the complete response rate increased to 71% [117]. In light of this study, canakinumab is started at 150 mg/month and, according to response, the dose can increase to a maximum of 300 mg/month or taper to 150 mg every other month. In daily practice, canakinumab injections are more comfortable than anakinra injections, which might improve treatment compliance [110].

Rilonacept, an IL-1 decoy receptor, binds to IL-1β and – to a lesser extent – IL-1α. Rilonacept is the least-studied and least-used IL-1 antagonist in FMF treatment. In a small RCT comprising 14 patients, two patients had a complete response while eight had a partial response and two had no response during a three-month treatment course [118].

Tocilizumab is a humanized monoclonal antibody against the interleukin-6 receptor, and it has potent suppressive effects in the production of APRs. Although FMF is considered an IL-1 mediated disease, serum IL-6 concentrations have been found to be elevated in FMF.
patients, particularly during attacks [119]. Yılmaz et al. treated 11 FMF amyloidosis patients with a monthly infusion of 8 mg/kg of tocilizumab for a duration of three to 16 months. Proteinuria improved or stabilized in eight patients, and no attacks were observed in ten patients [120]. After proteinuria normalization, the researchers discontinued tocilizumab in two patients, which resulted in a relapse of proteinuria for both patients [121]. Another study by Ugurlu et al. observed similar results [122]. Ongoing RCTs in Germany (NCT03446209) and Japan (UMIN000028010) will explore role of tocilizumab in treatment of crFMF and ciFMF patients.

9.2. Treatment of acute episodes
The therapeutic approach to an acute FMF episode is mainly supportive, including the administration of intravenous saline for hydration and the use of analgesics [97]. However, it has been suggested that the use of anakinra in the prodromal period might abrogate or alleviate the symptoms of an imminent attack [31,116]. Many patients report antecedent precipitating insults before attacks, and 70% of these insults were followed by an attack [123]. Therefore, use of anakinra soon after a powerful attack trigger would also be a reasonable approach. Anakinra can be used in acute attacks which are potentially life threatening, expected to be last longer or leave permanent damage, such as pericarditis, febrile myalgia and hip joint arthritis.

9.3. Treatment of comorbidities
As we mentioned earlier, various inflammatory conditions may accompany FMF. The treatment of these conditions is the same when they accompany FMF as their usual treatment in non-FMF patients. However, some of the successful reported treatments are disclosed in Table 3. Interestingly, some of the inflammatory comorbid conditions in the course of FMF may also respond well to IL-1 inhibitors, such as spondyloarthropathy, Behçet’s disease, inflammatory bowel disease, protracted febrile myalgia, hidradenitis suppurativa, pustular psoriasis, and HSP [108].

Chronic arthritis in FMF does not respond to colchicine alone and requires additional medications, such as disease-modifying antirheumatic drugs (DMARDs), intraarticular steroid injections, or biologics (Table 3). Similarly, protracted febrile myalgia is resistant to colchicine, which can be treated with glucocorticoids, NSAIDs, and IL-1 antagonists.

9.4. Treatment of complications
Colchicine can stabilize or even improve proteinuria in FMF-associated amyloidosis in colchicine-naïve or noncompliant patients with serum creatinine levels of <1.5 mg/dL, and the dose should not be less than 1.5 mg/day for such patients [100] though dose adjustment is necessary in the case of reduced creatinine clearance. Intensive blood pressure control should be maintained in all proteinuric subjects along with anti-lipidemic treatments. There is a significant correlation between serum SAA concentration and increased risk of death from amyloidosis, with ~4-, ~5-, and ~12-folds for values above 4, ~10, and ~45 mg/L, respectively [84]. Therefore, for patients with AA amyloidosis and ongoing inflammatory activity (preferably assessed with SAA or CRP) despite the maximum tolerated dose of colchicine, biologic treatments should be promptly initiated. The target SAA value would be less than 10 mg/L, since this cut-off has a 60% chance of regression.

Table 3. Selected comorbidities and reported successful treatments.

| Condition          | Treatment(s) | Study          | Reference                                |
|--------------------|--------------|----------------|------------------------------------------|
| Chronic arthritis  | DMARDs       | Case series    | [143,144]                                |
|                    | Anti-IL-1    | Case series    | [110]                                    |
|                    | Anti-TNF     | Case series    | [145,146]                                |
|                    | Tofacitinib  | Case series    | [147]                                    |
| Sacroiliitis       | Anti-TNF     | Case series    | [146]                                    |
|                    | Anti-IL-1    | Case series    | [148]                                    |
| AA Amyloidosis     | Anti-IL-1    | Case series    | [111,112,149,150]                        |
|                    | Anti-IL-6    | Case series    | [120,122,151–154]                        |
|                    | Interferon-α2a| Case          | [155]                                    |
|                    | Anti-TNF     | Case series    | [156,157]                                |
| PFM                | Anti-IL-1    | Case series    | [46,158,159]                             |

DMARDs: Disease modifying antirheumatic drugs, IL: Interleukin, PFM: Protracted febrile myalgia, TNF: Tumor necrosis factor.
in amyloid deposits and improved survival [84]. If SAA is not available, CRP values 5 mg/L in FMF children or 8.75 mg/L in FMF adults during attack-free periods can be a convenient substitute to guide therapeutic decisions [124]. The use of IL-1 inhibitors improves AA amyloidosis patients’ renal function [111,112].

End-stage renal disease caused by renal amyloidosis should be treated the same way as other causes of renal failure, including transplantation. After kidney transplantation, tight control of inflammation should be maintained, and colchicine drug interactions must be carefully assessed. Tight inflammation control may also improve complications other than AA amyloidosis, such as growth retardation and infertility. The use of IL-1 inhibitors has been shown to restore fertility in FMF patients suffering from infertility or subfertility [125].

9.5. Approach to patients with chronic subclinical inflammation

Chronic inflammation constitutes a substantial risk for AA amyloidosis, growth retardation, and cardiovascular disease [54]. In such cases, FMF disease activity must be carefully assessed using prospective patient diaries and in confirmed quiescent patients, all other possible causes of chronic inflammation should be ruled out, including inflammatory comorbidities and chronic infections [55]. In true asymptomatic patients, colchicine dose must be increased/maintained at maximum tolerated doses until SAA normalizes which has been demonstrated previously [98, 126]. Currently, there is no evidence to support routinely recommending IL-1 or IL-6 antagonists to patients in clinical remission but with elevated APRs. However, a vigilant follow-up for proteinuria and promptly initiating IL-1 or IL-6 antagonists when microalbuminuria is detected, and use of them in those at high risk of AA amyloidosis (presence of several risk factors) would be the reasonable approaches. One issue is that even in patients at high risk of amyloidosis, acceptance and adherence to IL-1 antagonists in the absence of symptoms is low.

10. Prognosis

FMF has an excellent prognosis if diagnosed and treated early, before complications develop. Serious complications almost always develop in colchicine-uncompliant or -resistant cases or among patients with delayed diagnoses. In a recent study, we found in a large cohort that more than half of FMF patients suffer from at least one disease complication [127], assessed by autoinflammatory disease damage index (ADDI) [5]. Damage mainly occur in the musculoskeletal, reproductive, and excretory systems – including growth retardation, pubertal delay, amenorrhea, infertility or subfertility, proteinuria, AA amyloidosis, kidney failure, serosal scarring and adhesions, musculoskeletal pain, joint deformity, and osteoporosis[127]. Risk factors for damage are M694V homozygosity, colchicine resistance/nonadherence, musculoskeletal attacks, diagnostic delay, disease duration and chronic inflammation [127]. Systemic AA amyloidosis is the leading cause of morbidity and mortality in FMF [128,129], therefore patients with defined risk factors should be meticulously followed (Table 4). After the diagnosis of AA amyloidosis, end stage renal disease develops in median five years and the 5-year survival rate was reported as 50% [130,131]. Allograft survival after transplantation is poorer in FMF associated amyloidosis than other causes of ESRD [132, 133].

Poor sleep quality, anxiety, depression and fatigue are frequently neglected health issues in FMF patients [134,135]. Work productivity is impaired in severe disease and can be improved with good control of disease with colchicine and IL-1 antagonists. Reports have suggested that FMF patients have significantly lower incidence of cancer than the general population [136, 137], raising speculations that MEFV can act as an oncosuppressor gene [138]. On the other hand, numerous reported cases describe mesothelioma in FMF, attributed to chronic serosal inflammation [138].

Table 4. Risk factors for AA amyloidosis.

| Characteristics                 | Fold risk increase | Reference                  |
|--------------------------------|--------------------|----------------------------|
| Male sex                       | 1.7–4              | [67,160]                   |
| Arthritis                      | 2.3 – 2.4          | [127,160,161]              |
| Very frequent attacks ≥20 per year | 2.0               | [74]                       |
| Family history of AA amyloidosis | 2.0               | [74]                       |
| Chronic inflammation           | 3.59–13            | [54,55]                    |
| M694V homozygosity             | 2.6–4.3            | [74,160]                   |
| SAA1 α/α genotype              | 3–6.9              | [67,160]                   |
| Living in Turkey, Middle East, Armenia vs. Europe | 1.5–3.2          | [74]                       |
11. Follow-up
After an FMF diagnosis, all of the patient's family members should be evaluated for the disease. Colchicine should be initiated immediately upon a clinical FMF diagnosis. Response, toxicity, and compliance should be monitored every three to six months. Persistence of attacks or subclinical inflammation represents disease activity and an indication to increase colchicine dosage [99]. Monitoring disease activity with a diary is probably the best way to assess the frequency and duration of attacks and to ascertain precipitating factors. Paper and mobile phone application versions (AIDD) of patient diaries exist, but patient adherence is poor. Wearable technology could be a promising tool to monitor disease activity by capturing attacks based on abrupt decline in routine physical activity [139].

Complete blood count, liver enzymes, creatinine, CRP or SAA, and urinalysis should be monitored every three to six months to monitor colchicine toxicity, inflammatory activity, and proteinuria [99]. A kidney biopsy is recommended whenever the urinary protein excretion exceeds 0.5 g/24 h to exclude AA amyloidosis [140]. More convenient sites for the tissue biopsies are abdominal fat and minor salivary glands [141]. The other option for patients with suspected amyloidosis is the use of a serum amyloid P (SAP) scan but it is only available at certain centers [142].

12. Future perspectives
Genetic testing, combined with functional assays, might be the diagnostic strategy in the near future, and it may also aid in treatment planning. Extension studies will disclose the long-term benefits of IL-1 antagonists in terms of preventing damage. Clinical trials could, moreover, investigate the efficacy of caspase inhibitors and more potent colchicine derivatives. Since FMF commonly results from missense mutations, CRISPR/Cas9 system could potentially provide a cure in the future.

13. Conclusion
FMF is an enigmatic disease in both its pathogenesis and clinical manifestations. Although FMF manifests with intermittent attacks, many patients suffer from complications of disease. Early diagnosis and adherence to treatment are key issues for the well-being of patients. Although the last 25 years has seen major progress regarding the pathogenesis, diagnosis and treatment of FMF, there are many questions awaiting their answers such as episodic nature of disease, variants of unknown significance, epigenetics and rational use of biologic drugs.

Disclaimers
Abdurrahman Tufan has received research grants from Pfizer Inc., and Novartis Pharmaceuticals.

References
1. Schnappauf O, Chae JJ, Kastner DL, Aksentijevich I. The pyrin inflammasome in health and disease. Frontiers in Immunology 2019; 10: 1745. doi: 10.3389/fimmu.2019.01745
2. Van Gorp H, Huang L, Saavedra P, Vuylsteke M, Asoaka T et al. Blood-based test for diagnosis and functional subtyping of familial Mediterranean fever. Annals of the Rheumatic Diseases 2020; 79 (7): 960-968. doi: 10.1136/annrheumdis-2019-216701
3. Demirkaya E, Acikel C, Hashkes P, Gattorno M, Gul A et al. Development and initial validation of international severity scoring system for familial Mediterranean fever (ISSF). Annals of the Rheumatic Diseases 2016; 75 (6): 1051-1056. doi: 10.1136/annrheumdis-2015-208671
4. Piram M, Kone-Paut I, Lachmann HJ, Frenkel J, Ozen S et al. Validation of the auto-inflammatory diseases activity index (AIDAI) for hereditary recurrent fever syndromes. Annals of the Rheumatic Diseases 2014; 73 (12): 2168-2173. doi: 10.1136/annrheumdis-2013-203666
5. Ter Haar NM, Annink KV, Al-Mayouf SM, Amaryan G, Anton J et al. Development of the autoinflammatory disease damage index (ADDI). Annals of the Rheumatic Diseases 2017; 76 (5): 821-830. doi: 10.1136/annrheumdis-2016-210092
6. Roman YM, Hernandez AV, White CM. The role of suppressing inflammation in the treatment of atherosclerotic cardiovascular disease. Annals of Pharmacotherapy 2020; 54 (10): 1021-1029. doi: 10.1177/1060028020922994
7. Consortium. TIF. Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. The International FMF Consortium - Cell 1997; 90 (4): 797-807. doi: 10.1016/s0092-8674(00)80539-5
8. Papin S, Duquesnoy P, Cazeneuve C, Pantel J, Coppey-Moisson M et al. Alternative splicing at the MEFV locus involved in familial Mediterranean fever regulates translocation of the marenostrin/pyrin protein to the nucleus. Human Molecular Genetics 2000; 9 (20): 3001-3009. doi: 10.1093/hmg/9.20.3001
9. Broz P, Pelegrin P, Shao F. The gasdermins, a protein family executing cell death and inflammation. Nature Reviews: Immunology 2020; 20 (3): 143-157. doi: 10.1038/s41577-019-0228-2
10. Heilig R, Broz P. Function and mechanism of the pyrin inflammasome. European Journal of Immunology 2018; 48 (2): 230-238. doi: 10.1002/eji.201746947
11. Van Gorp H, Saavedra PH, De Vosconcelos NM, Van Opdenbosch N, Vande Walle L et al. Familial Mediterranean fever mutations lift the obligatory requirement for microtubules in Pyrin inflammation activation. Proceedings of the National Academy of Sciences of the United States of America 2016; 113 (50): 14384-14389. doi: 10.1073/pnas.1613156113

12. Lachmann HJ, Lowe P, Felix SD, Rordorf C, Leslie K et al. In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes. Journal of Experimental Medicine 2009; 206 (5): 1029-1036. doi: 10.1084/jem.20082481

13. Apostolidou E, Skendros P, Kambas K, Mitroulis I, Konstantinidis T et al. Neutrophil extracellular traps regulate IL-1beta-mediated inflammation in familial Mediterranean fever. Annals of the Rheumatic Diseases 2016; 75 (1): 269-277. doi: 10.1136/annrheumdis-2014-205958

14. Touitou I. The spectrum of familial Mediterranean fever (FMF) mutations. European Journal of Human Genetics 2001; 9 (7): 473-483. doi: 10.1038/sj.ejhg.5200658

15. Yaşar Bilge S, Sari I, Solmaz D, Şenel S, Emmungil H et al. The distribution of MEFV mutations in Turkish FMF patients: multicenter study representing results of Anatolia. Turkish Journal of Medical Sciences 2019; 49 (2): 472-477. doi: 10.3906/sag-1809-100

16. Ben-Chetrit E, Yazici H. Familial Mediterranean fever: different faces around the world. Clinical and Experimental Rheumatology 2019; 37 Suppl 121(6): 18-22.

17. Accetturo M, D’Uggento AM, Portincasa P, Stella A. Improvement of MEFV gene variants classification to aid treatment decision making in familial Mediterranean fever. Rheumatology 2020; 59 (4): 754-761. doi: 10.1093/rheumatology/kez332

18. Booty MG, Chae JJ, Masters SL, Remmers EF, Barham B et al. Familial Mediterranean fever with a single MEFV mutation: where is the second hit? Arthritis and Rheumatology 2009; 60 (6): 1851-1861. doi: 10.1002/art.24569

19. Rowczenio DM, Youngstein T, Trojer H, Omoyinmi E, Baginska A et al. British kindred with dominant FMF associated with high incidence of AA amyloidosis caused by novel MEFV variant, and a review of the literature. Rheumatology 2020; 59 (3): 554-558. doi: 10.1093/rheumatology/kez334

20. Stoffels M, Szerpl A, Simon A, Netea MG, Plantinga TS et al. MEFV mutations affecting pyrin amino acid 577 cause autosomal dominant autoinflammatory disease. Annals of the Rheumatic Diseases 2014; 73 (2): 455-461. doi: 10.1136/annrheumdis-2012-202580

21. Camus D, Shinar Y, Aamar S, Langevitz P, Ben-Zvi I et al. ‘Silent’ carriage of two familial Mediterranean fever gene mutations in large families with only a single identified patient. Clinical Genetics 2012; 82 (3): 288-291. doi: 10.1111/j.1399-0004.2011.01785.x

22. Ben-Chetrit E, Touitou I. Familial Mediterranean Fever in the world. Arthritis Care & Research 2009; 61 (10): 1447-1453. doi: 10.1002/art.24458

23. Migita K, Izumi Y, Jiuchi Y, Iwanaga N, Kawahara C et al. Familial Mediterranean fever is no longer a rare disease in Japan. Arthritis Research & Therapy 2016; 18: 175. doi: 10.1186/s13075-016-1071-5

24. Onen F, Sumer H, Turkay S, Akyurek O, Tunca M et al. Increased frequency of familial Mediterranean fever in Central Anatolia, Turkey. Clinical and Experimental Rheumatology 2004; 22 (4 Suppl. 34): S31-S33.

25. Sohar E, Gafni J, Pras M, Heller H. Familial Mediterranean fever: a survey of 470 cases and review of the literature. American Journal of Medicine 1967; 43 (2): 227-253. doi: 10.1016/0002-9343(67)90167-2

26. Rigante D, Lopalco G, Tarantino G, Compagnone A, Fastiggi M et al. Non-canonical manifestations of familial Mediterranean fever: a changing paradigm. Clinical Rheumatology 2015; 34 (9): 1503-1511. doi: 10.1007/s10067-015-2916-x

27. Tamir N, Langevitz P, Zemer D, Pras E, Shinar Y et al. Late-onset familial Mediterranean fever (FMF): a subset with distinct clinical, demographic, and molecular genetic characteristics. American Journal of Medical Genetics 1999; 87 (1): 30-35.

28. Karadag O, Tufan A, Yazisiz V, Ureten K, Yilmaz S et al. The factors considered as trigger for the attacks in patients with familial Mediterranean fever. Rheumatology International 2013; 33 (4): 893-897. doi: 10.1007/s00296-012-2453-x

29. Kumei S, Nozu T, Ohira M, Miyagishi S, Okumura T. Cold exposure related fever with an Mediterranean fever (MEFV) gene mutation. Internal Medicine 2017; 56 (16): 2233-2236. doi: 10.2169/internalmedicine.8274-16

30. Lidar M, Yaqoubov M, Zaks N, Ben-Horin S, Langevitz P et al. The prodrome: a prominent yet overlooked pre-attack manifestation of familial Mediterranean fever. Journal of Rheumatology 2006; 33 (6): 1089-1092.

31. Babaoglu H, Atas N, Varan O, Satis H, Bilici Salman R et al. Frequency, characteristics, and clinical determinants of ‘prodrome’ in familial Mediterranean fever patients. Scandanavian Journal of Rheumatology 2020; 49 (2): 154-158. doi: 10.1080/03009742.2019.1638449

32. Kallinich T, Gattorno M, Sturz G, Traidl-Hoffmann C et al. Unexplained recurrent fever: when is autoinflammation the explanation? Allergy 2013 68 (3): 285-296. doi: 10.1111/all.12084

33. Nir-Paz R, Ben-Chetrit E, Pikarsky E, Hassin D, Hasin Y et al. Unusual presentation of familial Mediterranean fever: role of genetic diagnosis. Annals of the Rheumatic Diseases 2000; 59 (10): 836-838. doi: 10.1136/ard.59.10.836

34. Lee JH, Kim JH, Shin JO, Lee KC, Lee JW et al. Familial Mediterranean fever presenting as fever of unknown origin in Korea. Korean Journal of Pediatrics 2016; 59 (Suppl. 1): S53-S56. doi: 10.3345/kjp.2016.59.11.553

35. Mor A, Gal R, Livneh A. Abdominal and digestive system associations of familial Mediterranean fever. American Journal of Gastroenterology 2003; 98 (12): 2594-2604. doi: 10.1111/j.1572-0241.2003.08784.x
36. Livneh A, Langevitz P, Pras M. Pulmonary associations in familial Mediterranean fever. Current Opinion in Pulmonary Medicine 1999; 5 (5): 326-331. doi: 10.1097/00063198-199909000-00011

37. Lidar M, Pras M, Langevitz P, Livneh A. Thoracic and lung involvement in familial Mediterranean fever (FMF). Clinics in Chest Medicine 2002; 23 (2): 505-511. doi: 10.1016/s0272-5231(01)00002-8

38. Tunca M, Akar S, Onen F, Ozdogan H, Kasapcopur O et al. Familial Mediterranean Fever (FMF) in Turkey: results of a nationwide multicenter study. Medicine 2005; 84 (1): 1-11. doi: 10.1097/00015237.04628.0c

39. Erken E, Erken E. Cardiac disease in familial Mediterranean fever. Rheumatology International 2018; 38 (1): 51-58. doi: 10.1007/s00296-017-3853-8

40. Okutur K, Seber S, Oztekin E, Bes C, Borlu F. Recurrent pericarditis as the initial manifestation of familial Mediterranean fever. Medical Science Monitor 2008; 14 (12): CS139-CS141.

41. Yoshioka K, Furumitsu Y, Sano T, Miyamoto T, Agematsu K. Acute pericarditis as the first manifestation of familial Mediterranean fever: a possible relationship with idiopathic recurrent pericarditis. Internal Medicine 2014; 53 (15): 1659-1663. doi: 10.2169/internalmedicine.53.2064

42. Kasifoglu T, Calisir C, Cansu DU, Korkmaz C. The frequency of sacroiliitis in familial Mediterranean fever and the role of HLA-B27 and MEFV mutations in the development of sacroiliitis. Clinical Rheumatology 2009; 28 (1): 41-46. doi: 10.1007/s10067-008-0980-3

43. Olgun A, Akman S, Kurt I, Tuzun A, Kutluay T. MEFV mutations in familial Mediterranean fever: association of M694V homozygosity with arthritis. Rheumatology International 2005; 25 (4): 255-259. doi: 10.1007/s00296-003-0433-x

44. Bayram MT, Çankaya T, Bora E, Kavukçu S, Uğenalp A et al. Risk factors for subclinical inflammation in children with Familial Mediterranean fever. Rheumatology International 2015; 35 (8): 1393-1398. doi: 10.1007/s00296-015-3227-z

45. Eshed I, Rosman Y, Livneh A, Kedem R, Langevitz P et al. Exertional leg pain in familial Mediterranean fever: a manifestation of an underlying enthesopathy and a marker of more severe disease. Arthritis & Rheumatism 2014; 66 (11): 3221-3226. doi: 10.1002/art.38797

46. Mercan R, Turan A, Bitik B, Tufan A, Haznedaroglu S et al. Rapid resolution of protracted febrile myalgia syndrome with anakinra: report of two cases. Modern Rheumatology 2016; 26 (3): 458-459. doi: 10.3109/14397595.2014.882221

47. Ben-Chetrit E, Peleg H, Aamar S, Heyman SN. The spectrum of MEFV clinical presentations-is it familial Mediterranean fever only? Rheumatology 2009; 48 (11): 1455-1459. doi: 10.1093/rheumatology/kep296

48. Atas N, Armagan B, Bodakci E, Satis H, Sari A et al. Familial Mediterranean fever is associated with a wide spectrum of inflammatory disorders: results from a large cohort study. Rheumatology International 2020; 40 (1): 41-48. doi: 10.1007/s00296-019-04412-7

49. Watad A, Bragazzi NL, Adawi M, Shoenfeld Y, Comaneshter D et al. FMF is associated with a wide spectrum of MHC class I- and allied SpA disorders but not with classical MHC class II-associated autoimmune disease: insights from a large cohort study. Frontiers in Immunology 2019; 10: 2733. doi: 10.3389/fimmu.2019.02733

50. Balci-Peyircioglu B, Kaya-Akca Ü, Arici ZS, Avci E, Akkaya-Ulum ZY et al. Comorbidities in familial Mediterranean fever: analysis of 2000 genetically confirmed patients. Rheumatology 2020; 59 (6): 1372-1380. doi: 10.1093/rheumatology/kez410

51. Yildiz M, Adrovic A, Tasdemir E, Baba-Zada K, Aydin M et al. Evaluation of co-existing diseases in children with familial Mediterranean fever. Rheumatology International 2020; 40 (1): 57-64. doi: 10.1007/s00296-019-04391-9

52. Ayaz NA, Tanatar A, Karadag SG, Cakan M, Keskindemirici G et al. Comorbidities and phenotype-genotype correlation in children with familial Mediterranean fever. Rheumatology International 2020. doi: 10.1007/s00296-020-04592-7

53. Lachmann HJ, Sengul B, Yavuzsen TU, Booth DR, Booth SE et al. Clinical and subclinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations. Rheumatology 2006; 45 (6): 746-750. doi: 10.1093/rheumatology/kei279

54. Babaoglu H, Armagan B, Bodakci E, Satis H, Atas N et al. Predictors of persistent inflammation in familial Mediterranean fever and association with damage. Rheumatology 2020. doi: 10.1093/rheumatology/keac378

55. Varan O, Kucuk H, Babaoglu H, Tecer D, Atas N et al. Chronic inflammation in adult familial Mediterranean fever patients: underlying causes and association with amyloidosis. Scandinavian Journal of Rheumatology 2019; 48 (4): 315-319. doi: 10.1080/03009742.2018.1558282

56. Gohar F, Orak B, Kallinich T, Jeske M, Lieber M et al. Correlation of Secretory Activity of Neutrophils With Genotype in Patients With Familial Mediterranean Fever. Arthritis & Rheumatism 2016; 68 (12): 3010-3022. doi: 10.1002/art.39784

57. Dewalle M, Domingo C, Rozenbaum M, Ben-Chetrit E, Cattan D et al. Phenotype-genotype correlation in Jewish patients suffering from familial Mediterranean fever (FMF). European Journal of Human Genetics 1999; 6 (1): 95-97. doi: 10.1038/sj.ejhg.5200170

58. Kunt SS, Aydin F, Cakar N, Ozdel S, Yalcinkaya F et al. The effect of genotype on musculoskeletal complaints in patients with familial Mediterranean fever. Postgraduate Medicine 2020; 132 (2): 220-224. doi: 10.1080/03009742.2019.1708147

59. Grossman C, Kassel Y, Livneh A, Ben-Zvi I. Familial Mediterranean fever (FMF) phenotype in patients homozygous to the MEFV M694V mutation. European Journal of Medical Genetics 2019; 62 (6): 103532. doi: 10.1016/j.ejmg.2018.08.013

60. Hentgen V, Grateau G, Stankovic-Stojanovic K, Amselem S, Jeru I. Familial Mediterranean fever in heterozygotes: are we able to accurately diagnose the disease in very young children? Arthritis and Rheumatology 2013; 65 (6): 1654-1662. doi: 10.1002/art.37935
85. Holzinger D, Foell D, Kessel C. The role of S100 proteins in the pathogenesis and monitoring of autoinflammatory diseases. Molecular and Cellular Pediatrics 2018; 5 (1): 7. doi: 10.1186/s40348-018-0085-2

86. Ozaltin F, Bilginer Y, Gulhan B, Bajin I, Erdogan O et al. Diagnostic validity of colchicine in patients with familial Mediterranean fever. Clinical Rheumatology 2014; 33 (7): 969-974. doi: 10.1007/s10067-014-2598-y

87. Knieper AM, Klotsche J, Lainka E, Berger T, Dressler F et al. Familial Mediterranean fever in children and adolescents: factors for colchicine dosage and predicting parameters for dose increase. Rheumatology 2017; 56 (9): 1597-1606. doi: 10.1093/rheumatology/kek222

88. Zemer D, Pras M, Sohar E, Modan B, Cabili S et al. Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. New England Journal of Medicine 1986; 314 (16): 1001-1005. doi: 10.1056/NEJM198604173141601

89. Kasifoglu T, Bilge SY, Sari I, Solmaz D, Senel S et al. Amyloidosis and its related factors in Turkish patients with familial Mediterranean fever: a multicentre study. Rheumatology 2014; 53 (4): 741-745. doi: 10.1093/rheumatology/ket400

90. Zemer D, Revach M, Pras M, Modan B, Schor S et al. A controlled trial of colchicine in preventing attacks of familial Mediterranean fever. New England Journal of Medicine 1974; 291 (18): 932-934. doi: 10.1056/NEJM197410312911803

91. Dinarello CA, Wolff SM, Goldfinger SE, Dale DC, Alling DW. Colchicine therapy for familial Mediterranean fever: a double-blind trial. New England Journal of Medicine 1974; 291 (18): 934-937. doi: 10.1056/NEJM197410312911804

92. Levy M, Eliakim M. Long-term colchicine prophylaxis in familial Mediterranean fever. British Medical Journal 1977; 2 (6090): 808. doi: 10.1136/bmj.2.6090.808

93. Goldstein RC, Schwabe AD. Prophylactic colchicine therapy in familial Mediterranean fever: a controlled, double-blind study. Annals of Internal Medicine 1974; 81 (6): 792-794. doi: 10.7326/0003-4819-81-6-792

94. Slobodnick A, Shah B, Pillinger MH, Krasnokutsky S, Colchicine: old and new. American Journal of Medicine 2015; 128 (5): 461-470. doi: 10.1016/j.amjmed.2014.12.010

95. Ben-Chetrit E, Levy M. Does the lack of the P-glycoprotein efflux pump in neutrophils explain the efficacy of colchicine in familial Mediterranean fever and other inflammatory diseases? Medical Hypotheses 1998; 51 (5): 377-380. doi: 10.1016/s0306-9877(98)90031-7

96. Ozen S, Kone-Paut I, Gul A. Colchicine resistance and intolerance in familial Mediterranean fever: definition, causes, and alternative treatments. Seminars in Arthritis and Rheumatism 2017; 47 (1): 115-120. doi: 10.1016/j.semarthrit.2017.03.006

97. Ozturk MA, Kanbay M, Kasapoglu B, Onat AM, Guz G et al. Therapeutic approach to familial Mediterranean fever: a review update. Clinical and Experimental Rheumatology 2011; 29 (4 Suppl. 67): S77-S86.

98. Kallinich T, Haffner D, Niehuess T, Huss K, Lainka E et al. Colchicine use in children and adolescents with familial Mediterranean fever: literature review and consensus statement. Pediatrics 2007; 119 (2): e474-483. doi: 10.1542/peds.2006-1434

99. Ozen S, Demirkaya E, Erer B, Livneh A, Ben-Chetrit E et al. EULAR recommendations for the management of familial Mediterranean fever. Annals of the Rheumatic Diseases 2016; 75 (4): 644-651. doi: 10.1136/annrheumdis-2015-208690

100. Livneh A, Zemer D, Lavevitz P, Laor A, Sohar E et al. Colchicine treatment of AA amyloidosis of familial Mediterranean fever. Arthritis and Rheumatology. 1994; 37 (12): 1804-1811. doi: 10.1002/art.1780371215

101. Satış H, Armağan B, Bodakçı E, Ataş N, Sarı A et al. Colchicine intolerance in FMF patients and primary obstacles for optimal dosing. Turkish Journal of Medical Sciences 2020; 50: 1337-1343. doi: 10.3906/sag-2001-261

102. Zemer D, Livneh A, Danon YL, Pras M, Sohar E. Long-term colchicine treatment in children with familial Mediterranean fever. Arthritis and Rheumatology 1991; 34 (8): 973-977. doi: 10.1002/art.1780340806

103. Ozckar ZB, Elhan AH, Yalcinkaya F. Can colchicine response be predicted in familial Mediterranean fever patients? Rheumatology 2014; 53 (10): 1767-1772. doi: 10.1093/rheumatology/keu138

104. Ben-Zvi I, Krichely-Vachdi T, Feld O, Lidar M, Kivity S et al. Colchicine-free remission in familial Mediterranean fever: featuring a unique subset of the disease-a case control study. Orphanet Journal of Rare Diseases 2014; 9: 3. doi: 10.1186/1750-1172-9-3

105. Tanatar A, Karadag SG, Sonmez HE, Cakan M, Aktay Ayaz N. Short-term follow-up results of children with familial Mediterranean fever after cessation of colchicine: is it possible to quit? Rheumatology 2019; 58 (10): 1818-1821. doi: 10.1093/rheumatology/kez156

106. Sag E, Eldad Ben-Chetrit E, Gattorno M, Gul A, Hashkes P et al. Recommendation on colchicine dosing and definition of colchicine resistance/intolerance in the management of familial Mediterranean fever. In: ACR/ARP Annual Meeting; Atlanta, GA, USA; 2019.

107. Corsia A, Georgin-Lavialle S, Hentgen V, Hachulla E, Grateau G et al. A survey of resistance to colchicine treatment for French patients with familial Mediterranean fever. Orphanet Journal of Rare Diseases 2017; 12 (1): 54. doi: 10.1186/s13023-017-0609-1

108. Hentgen V, Vinit C, Fayand A, Georgin-Lavialle S. The use of interleukin-1 inhibitors in familial Mediterranean fever patients: a narrative review. Frontiers in Immunology 2020; 11 (971): 971. doi: 10.3389/fimmu.2020.00971

109. Vanan O, Kucuk H, Banaoglu H, Atas N, Salman RB et al. Effect of interleukin-1 antagonists on the quality of life in familial Mediterranean fever patients. Clinical Rheumatology 2019; 38 (4): 1125-1130. doi: 10.1007/s10067-018-4384-8

1607
110. Babaoglu H, Varan O, Kucuk H, Atas N, Satis H et al. Effectiveness of canakinumab in colchicine- and anakinra-resistant or -intolerant adult familial Mediterranean fever patients: a single-center real-life study. Journal of Clinical Rheumatology 2020; 26 (1): 7-13. doi: 10.1097/RHU.0000000000000873

111. Akar S, Cetin P, Kalyoncu U, Karadag O, Sari I et al. Nationwide experience with off-label use of interleukin-1 targeting treatment in familial Mediterranean fever patients. Arthritis Care & Research 2018; 70 (7): 1090-1094. doi: 10.1002/acr.23446

112. Varan O, Kucuk H, Babaoglu H, Guven SC, Ozturk MA et al. Efficacy and safety of interleukin-1 inhibitors in familial Mediterranean fever patients complicated with amyloidosis. Modern Rheumatology 2019; 29 (2): 363-366. doi: 10.1080/14397595.2018.1457469

113. Ben-Zvi I, Kukuy O, Giat E, Pras E, Feld O et al. Anakinra for colchicine-resistant familial Mediterranean fever: a randomized, double-blind, placebo-controlled trial. Arthritis Rheumatology 2017; 69 (4): 854-862. doi: 10.1002/art.39995

114. Harrison SR, McGonagle D, Nizam S, Jarrett S, Van der Hilst J et al. Anakinra as a diagnostic challenge and treatment option for systemic autoinflammatory disorders of undefined etiology. JCI Insight 2016; 1 (6): e86336. doi: 10.1172/jci.insight.86336

115. Babaoglu H, Varan O, Kucuk H, Turan A, Tufan A. Osteitis as a manifestation of familial Mediterranean fever. Rheumatology 2017; 56 (11): 2035-2036. doi: 10.1093/rheumatology/kex294

116. Babaoglu H, Varan O, Kucuk H, Atas N, Satis H et al. On demand use of anakinra for attacks of familial Mediterranean fever (FMF). Clinical Rheumatology 2019; 38 (2): 577-581. doi: 10.1007/s10067-018-4230-z

117. De Benedetti F, Gattorno M, Anton J, Ben-Chetrit E, Frenkel J et al. Canakinumab for the treatment of autoinflammatory recurrent fever syndromes. New England Journal of Medicine 2018; 378 (20): 1908-1919. doi: 10.1056/NEJMoa1706314

118. Hashkes PJ, Spalding SJ, Giannini EH, Huang B, Johnson A et al. Rilonacept for colchicine-resistant or -intolerant familial Mediterranean fever: a randomized trial. Annals of Internal Medicine 2012; 157 (8): 533-541. doi: 10.7326/0003-4819-157-8-201210160-00003

119. Koga T, Migita K, Sato S, Umeda M, Nonaka F et al. Multiple serum cytokine profiles to identify combinatorial diagnostic biomarkers in attacks of familial Mediterranean fever. Medicine 2016; 95 (16): e3449. doi: 10.1097/MD.0000000000003449

120. Yılmaz S, Cinar M, Simsek I, Erdem H, Pay S. Tocilizumab in the treatment of patients with AA amyloidosis secondary to familial Mediterranean fever. Rheumatology 2015; 54 (3): 564-565. doi: 10.1093/rheumatology/keu474

121. Yılmaz S, TCGez O, Cinar M. Recurrence of proteinuria after cessation of tocilizumab in patients with AA amyloidosis secondary to FMF. European Journal of Rheumatology 2018; 5 (4): 278-280. doi: 10.5152/eurjrheum.2018.17183

122. Ugurlu S, Hacioglu A, Adibnia Y, Hamuryuden V, Ozdogan H. Tocilizumab in the treatment of twelve cases with aa amyloidosis secondary to familial Mediterranean fever. Orphanet Journal of Rare Diseases 2017; 12 (1): 105. doi: 10.1186/s13023-017-0642-0

123. Yenokyan G, Armenian HK. Triggers for attacks in familial Mediterranean fever: application of the case-crossover design. American Journal of Epidemiology 2012; 175 (10): 1054-1061. doi: 10.1093/aje/kwr460

124. Stankovic-Stojanovic K, Hentgen V, Fellahi S, Georgin-Lavialle S, Amselem S et al. Concordance between CRP and SAA in familial Mediterranean fever during attack-free period: a study of 218 patients. Clinical Biochemistry 2017; 50 (4-5): 206-209. doi: 10.1016/j.clinbiochem.2016.11.008

125. Babaoglu H, Varan O, Kucuk H, Atas N, Satis H et al. Familial Mediterranean fever-associated infertility and underlying factors. Clinical Rheumatology 2020; 39 (1): 255-261. doi: 10.1007/s10067-019-04773-1

126. Duzova A, Bakkaloglu A, Besbas N, Topaloglu R, Ozen S et al. Role of A-SAA in monitoring subclinical inflammation and in colchicine dosage in familial Mediterranean fever. Clinical and Experimental Rheumatology 2003; 21 (4): 509-514.

127. Babaoglu H, Armanag B, Bodakci E, Satis H, Atas N et al. Factors associated with damage in patients with familial Mediterranean fever. Clinical and Experimental Rheumatology 2020.

128. Twig G, Livneh A, Vivante A, Afek A, Shamiss A et al. Mortality risk factors associated with familial Mediterranean fever among a cohort of 1.25 million adolescents. Annals of the Rheumatic Diseases 2014; 73 (4): 704-709. doi: 10.1136/annrheumdis-2012-202932

129. Akar S, Yuksel F, Tunca M, Soysal O, Solmaz D et al. Familial Mediterranean fever: risk factors, causes of death, and prognosis in the colchicine era. Medicine 2012; 91 (3): 131-136. doi: 10.1097/MD.0b013e3182561a45

130. Abbasap, Kara E, Sahutoglu T, Basturk T, Koc Y et al. Outcome of 121 patients with renal amyloid a amyloidosis. Journal of Research in Medical Sciences 2014; 19 (7): 644-649.

131. Ayar Y, Ersoy A, Oksuz MF, Ocakoglu G, Vuruskan BA et al. Clinical outcomes and survival in AA amyloidosis patients. Revista Brasileira de Reumatologia 2017; 57 (6): 535-544. doi: 10.1016/j.rbr.2017.02.002

132. Sarihan I, Caliskan Y, Mirioglu S, Ozluk Y, Senates B et al. AA amyloidosis after renal transplantation: an important cause of mortality. Transplantation 2019. doi: 10.1097/TP.0000000000003043

133. Green H, Lichtenberg S, Rahamimov R, Livneh A, Chagnac A et al. Familial Mediterranean fever is associated with increased mortality after kidney transplantation—a 19 years' single center experience. Transplantation 2017; 101 (10): 2621-2626. doi: 10.1097/TP.0000000000001681
Deger SM, Ozturk MA, Demirag MD, Aslan S, Goker B et al. Health-related quality of life and its associations with mood condition in familial Mediterranean fever patients. Rheumatology International 2011; 31 (5): 623-628. doi: 10.1007/s00296-009-1334-4

Sonmez AO, Sonmez HE, Ozen S, Keskindemirci G et al. The evaluation of anxiety, depression and quality of life scores of children and adolescents with familial Mediterranean fever. Rheumatology International 2020; 40 (5): 757-763. doi: 10.1007/s00296-020-04519-2

Brenner R, Ben-Zvi I, Shinar Y, Lipshitz I, Silverman B et al. Familial Mediterranean fever and incidence of cancer: an analysis of 8,534 Israeli patients with 258,803 person-years. Arthritis Rheumatology 2018; 70 (1): 127-133. doi: 10.1002/art.40344

Talerico R, Cardillo C, De Vito F, Schinzari F, Soldato M et al. Mesothelioma in familial Mediterranean fever with colchicine intolerance: a case report and literature review. Frontiers in Immunology 2020; 11: 889. doi: 10.3389/fimmu.2020.00889

Babaoglu H, Varan O, Atas N, Satis H, Salman R et al. Detection of familial Mediterranean fever attacks by using a connected activity tracker and assessment of impact of attacks to daily physical activities: a pilot study. Clinical Rheumatology 2019; 38 (7): 1941-1946. doi: 10.1007/s10067-019-04493-6

Kukuy O, Livneh A, Ben-David A, Kopolovic J, Volkov A et al. Familial Mediterranean fever (FMF) with proteinuria: clinical features, histology, predictors, and prognosis in a cohort of 25 patients. Journal of Rheumatology 2013; 40 (12): 2083-2087. doi: 10.3899/jrheum.130520

Mercan R, Bitik B, Tezcan ME, Kaya A, Tufan A et al. Minimally invasive minor salivary gland biopsy for the diagnosis of amyloidosis in a rheumatology clinic. ISRN Rheumatology 2014; 2014: 354648. doi: 10.1155/2014/354648

Papa R, Lachmann HJ. Secondary, AA, amyloidosis. Rheumatic Diseases Clinics of North America 2018; 44 (4): 585-603. doi: 10.1016/j.rdc.2018.06.004

Bakkaloglu SA, Aksu T, Goker B, Unlusoy A, Peru H et al. Sulphasalazine treatment in protracted familial Mediterranean fever arthritis. European Journal of Pediatrics 2009; 168 (8): 1017-1019. doi: 10.1007/s00431-008-0875-y

Langevitz P, Livneh A, Zemer D, Shemer J, Pras M. Seronegative spondyloarthritis in familial Mediterranean fever. Seminars in Arthritis and Rheumatism 1997; 27 (2): 67-72. doi: 10.1016/s0049-0172(97)80007-8

Sakallioglu O, Duzova A, Ozen S. Etanercept in the treatment of arthritis in a patient with familial Mediterranean fever. Clinical and Experimental Rheumatology 2006; 24 (4): 435-437.

Bilgen SA, Kılıc L, Akdoğan A, Kiraz S, Kayyoncu U et al. Effects of anti-tumor necrosis factor agents for familial Mediterranean fever patients with chronic arthritis and/or sacroiliitis who were resistant to colchicine treatment. Journal of Clinical Rheumatology 2011; 17 (7): 358-362. doi: 10.1097/ RHU.0b013e31823682f5

Karadeniz H, Guler AA, Atas N, Satis H, Salman RB et al. Tofacitinib for the treatment for colchicine-resistant familial Mediterranean fever: case-based review. Rheumatology International 2020; 40 (1): 169-173. doi: 10.1007/s00296-019-04490-7

Varan O, Kucuk H, Tufan A. Anakinra for the treatment of familial Mediterranean fever-associated spondyloarthritis. Scandinavian Journal of Rheumatology 2016; 45 (3): 252-253. doi: 10.1093/nr/ndt/jgr528

Stankovic Stojanovic K, Delmas Y, Torres PU, Peltier J, Pelle G et al. Dramatic beneficial effect of interleukin-1 inhibitor treatment in patients with familial Mediterranean fever complicated with amyloidosis and renal failure. Nephrology, Dialysis, Transplantation 2012; 27 (5): 1898-1901. doi: 10.1093/ ndt/gfr528

Ozccakar ZB, Oxzel S, Yilmaz S, Kurt-Sukur ED, Ekim M et al. Anti-IL-1 treatment in familial Mediterranean fever and related amyloidosis. Clinical Rheumatology 2016; 35 (2): 441-446. doi: 10.1007/s10067-014-2772-2

Lan T, Gillmore JD, Wechalekar AD, Hawkins PN, Lachmann HJ. Therapeutic blockade of interleukin-6 by tocilizumab in the management of AA amyloidosis and chronic inflammatory disorders: a case series and review of the literature. Clinical and Experimental Rheumatology 2015; 33 (6 Suppl. 94): S46-S53.

Courties A, Gradeau G, Philippe P, Flipo RM, Astudillo L et al. AA amyloidosis treated with tocilizumab: case series and updated literature review. Amyloid 2015; 22 (2): 84-92. doi: 10.3109/13506129.2015.1002031

Hamanoue S, Suwabe T, Hoshino J, Sumida K, Mise K et al. Successful treatment with humanized anti-interleukin-6 receptor antibody (tocilizumab) in a case of AA amyloidosis complicated by familial Mediterranean fever. Modern Rheumatology 2016; 26 (4): 610-613. doi: 10.1007/s10067-014-2772-2

Serelis J, Christaki S, Skopoulis FN. Renission of nephrotic syndrome due to AA-amyloidosis, complicating familial Mediterranean fever, with tocilizumab. Clinical and Experimental Rheumatology 2015; 33 (6 Suppl. 94): S46-S53.

Vandecasteele SJ, De Paepe P, De Vriese AS. Successful treatment of renal AA amyloidosis in familial Mediterranean fever with pegylated alpha-2a interferon. Clinical Nephrology 2011; 75 (Suppl. 1): 1-3. doi: 10.3109/03009742.2011.1002031

Ozccakar ZB, Yaksel S, Ekim M, Yalcinkaya F. Infliximab therapy for familial Mediterranean fever-related amyloidosis: case series with long term follow-up. Clinical Rheumatology 2012; 31 (8): 1267-1271. doi: 10.1007/s10067-012-2009-1
157. Erten S, Erten SF, Altunoglu A. Successful treatment with anti-tumor necrosis factor (anti-TNF)-alpha of proteinuria in a patient with familial Mediterranean fever (FMF) resistant to colchicine: anti-TNF drugs and FMF. Rheumatology International 2012; 32 (4): 1095-1097. doi: 10.1007/s00296-011-1855-5

158. Cakan M, Karadag SG, Ayaz NA. Corticosteroid-resistant anakinra-responsive protracted febrile myalgia syndrome as the first manifestation of familial Mediterranean fever. Northern Clinics of Istanbul 2020; 7 (1): 78-80. doi: 10.14744/nci.2019.38243

159. Yildirim DG, Bakkaloglu SA, Buyan N. Protracted febrile myalgia as a challenging manifestation of familial Mediterranean fever: case-based review. Rheumatology International 2019; 39 (1): 147-152. doi: 10.1007/s00296-018-4163-5

160. Gershoni-Baruch R, Brik R, Zacks N, Shinawi M, Lidar M et al. The contribution of genotypes at the MEFV and SAA1 loci to amyloidosis and disease severity in patients with familial Mediterranean fever. Arthritis and Rheumatology 2003; 48 (4): 1149-1155. doi: 10.1002/art.10944

161. Mukhin NA, Kozlovskaya LV, Bogdanova MV, Rameev VV, Moiseev SV et al. Predictors of AA amyloidosis in familial Mediterranean fever. Rheumatology International 2015; 35 (7): 1257-1261. doi: 10.1007/s00296-014-3205-x